V350A and V350B Vaccines for Healthy Adults
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
- Age
- 12 – 30
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 250 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
This trial is looking for healthy adults aged 18 to 30 or adolescents aged 12 to 17 to test new vaccines V350A and V350B. Participants will help researchers learn about the safety of these vaccines.
You may be able to join if
- I am in good health before randomization.
- I have a body mass index between 18 and 38 kg/m².
- I have a body mass index between 15 and 38 kg/m².
You may not be able to join if
- I have had a confirmed or suspected case of infectious mononucleosis in the past 12 months.
- I have any immunosuppressive medical condition.
- I receive any immunosuppressive therapy.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityEpstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Loading trial locations…